Chen L, Wang R, Gao L, Shi W.
Opa-Interacting Protein 5 Expression in Human Glioma Tissues Is Essential to the Biological Function of U251 Human Malignant Glioma Cells.
Cancer Control 2021;
27:1073274820968914. [PMID:
33153318 PMCID:
PMC7791457 DOI:
10.1177/1073274820968914]
[Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
Opa-interacting protein 5 (OIP5) is a member of the cancer-testis antigen (CTA)
family that elicits a spontaneous antitumor immune response. The failure of
current immunotherapies for glioma has prompted the search for novel biomarkers
that may be utilized as therapeutic targets. This study aimed to investigate
whether OIP5 serves as a target for malignant glioma immunotherapy. Glioma
specimens from 53 adult patients were evaluated for OIP5 expression by
immunohistochemical (IHC) staining, and the correlation of OIP5 expression with
World Health Organization (WHO) tumor grade was analyzed. Endogenous expression
of OIP5 in glioma cell lines was determined via real-time polymerase chain
reaction (RT-PCR). Using lentiviral siOIP5, the effect of OIP5 gene knockdown on
proliferation, cell cycle, and apoptosis in U251 glioma cells was studied. The
results show that OIP5 is overexpressed in glioma tissues and is correlated with
WHO tumor grade (P < 0.001). However, OIP5 protein
expression is barely detectable in normal adult brain tissues. MTT assays and
analysis using the Celigo Imaging Cytometry System reveal that the silencing of
OIP5 inhibits U251 cell growth. Cell cycle assays and Annexin V staining show
that OIP5 silencing disrupts the balance of the cell cycle and increases U251
cell death. These results indicate that OIP5 is upregulated in malignant glioma
specimens but barely detected in normal brain tissues. OIP5 knockdown inhibits
the biological function of glioma cells, reinforcing that OIP5 may serve as an
immunotherapeutic target for malignant glioma.
Collapse